All In Biotech

Drug Trial Radar · NCT03739684

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

208

Actual

Start

Nov 27, 2018

Primary completion

Aug 29, 2019

Study completion Aug 29, 2019

Sponsor

Sponsor type
Industry
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Conditions

  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic

Interventions

  • 18F-DCFPyLDrug

    A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL

  • PET/CT ImagingDiagnostic test

    PET/CT imaging will be acquired 1-2 hours post-PyL injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correct Localization Rate (CLR)Time frame: Within 60 days following 18F-DCFPyL PET/CT imaging.

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Tower Urology

    Los Angeles, California

  • University of California San Francisco - Helen Diller Cancer Center

    San Francisco, California

  • Stanford

    Stanford, California

  • Yale University

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University - Mallinckrodt Institute of Radiology

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Wisconsin

    Madison, Wisconsin

  • Chu de Quebec - Universite Laval

    Québec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.